Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. We are focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting GPCRs with small molecules that have specifically tailored pharmacology and properties. Our lead product, PALSONIFY (paltusotine), is the first once-daily, oral treatment approved by the FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $25M in Q2 2026 (quarter ended Jun 30, 2026), up 2336% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $121M. For the full year FY2025, revenue was $7.7M (+641% year on year) and net income −$465M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.